Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김태환 | - |
dc.date.accessioned | 2018-03-22T07:14:41Z | - |
dc.date.available | 2018-03-22T07:14:41Z | - |
dc.date.issued | 2013-06 | - |
dc.identifier.citation | Annals of the Rheumatic Diseases, 2013, 72(3), P.322-322 | en_US |
dc.identifier.issn | 0003-4967 | - |
dc.identifier.uri | http://ard.bmj.com/content/72/Suppl_3/A322.1 | - |
dc.identifier.uri | http://hdl.handle.net/20.500.11754/50682 | - |
dc.description.abstract | Background Adult onset Still’s disease (AOSD) is a systemic inflammatory disorder with unknown etiology. As therapeutic agents, traditional disease modifying anti-rheumatic drugs (DMARDs) or biological agents are suggested for patients unresponsive to corticosteroid. Among important cytokines for the AOSD pathogenesis, IL-6 plays a pivotal role. Several case reports have suggested that tocilizumab, a humanized anti-interleukin (IL)-6 receptor antibody was effective for intractable AOSD.Objectives Here, we described the clinical course of refractory Korean patients treated with tocilizumab therapy.Methods The 8 patients who were refractory to DMARDs and/or etarnecept or dependent to corticosteroid were enrolled for tocilizumab therapy after informed contents. Tocilizumab at 8mg/kg was administered every 4 weeks.Results Six females and 2 males were treated with tocilizumab. The mean age was 33.8 (26-47) years old. The frequency of tocilizumab therapy was an average of 6.3 (2-13) times. Almost patients showed complete (50.0%) or partial (37.5%) response to tocilizumab therapy except one patient (Table 1). The clinical symptoms improved in 4 weeks (mean), erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) improved in 6.3 weeks, respectively. Serum ferritin, IL-18 and IL-6 levels slowly improved within 9.3 weeks, 12.5 weeks and 9.3 weeks, respectively. Three patients discontinued tocilizumab therapy although they showed improvement of clinical symptoms; because of severe headache and chest discomfort at 12 weeks, neutropenia at 8 weeks, and severe hepatotoxicity at 8 weeks, respectively. Other adverse events such as mild dizziness, hair loss, weight gain and transient leucopenia were observed and those were tolerable during follow-up. | en_US |
dc.language.iso | en | en_US |
dc.publisher | BMJ PUBLISHING GROUP | en_US |
dc.title | PILOT TRIAL OF TOCILIZUMAB FOR REFRACTORY PATIENTS WITH ADULT ONSET STILL'S DISEASE | en_US |
dc.type | Article | en_US |
dc.relation.volume | 72 | - |
dc.identifier.doi | 10.1136/annrheumdis-2013-eular.994 | - |
dc.relation.page | 322-322 | - |
dc.relation.journal | ANNALS OF THE RHEUMATIC DISEASES | - |
dc.contributor.googleauthor | Kim, J. J. | - |
dc.contributor.googleauthor | Na, K. S | - |
dc.contributor.googleauthor | Kim, T. H. | - |
dc.contributor.googleauthor | Yoo, D. H | - |
dc.relation.code | 2013008904 | - |
dc.sector.campus | S | - |
dc.sector.daehak | COLLEGE OF MEDICINE[S] | - |
dc.sector.department | DEPARTMENT OF MEDICINE | - |
dc.identifier.pid | thkim | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.